Results 51 to 60 of about 4,988 (166)
Brazilian Journal of Medical and Biological Research, 2005 Beta-2-agonists have been widely used by asthmatic subjects to relieve their obstructive symptoms. However, there are reports that continuous use could lead to loss of bronchial protection and exacerbation of asthma symptoms.
Kasahara D.I. +5 more
doaj
Mouse Protocadherin-1 gene expression is regulated by cigarette smoke exposure in vivo [PDF]
, 2014 Protocadherin-1 (PCDH1) is a novel susceptibility gene for airway hyperresponsiveness, first identified in families exposed to cigarette smoke and is expressed in bronchial epithelial cells.
A Kicic +45 more
core +5 more sources
On the health effects of curcumin and its derivatives
Food Science &Nutrition, Volume 12, Issue 11, Page 8623-8650, November 2024.Curcuma longa has therapeutic properties that have gained prodigious consideration from scientists in the medical field—review of the existing clinical and animal studies of curcumin and its by‐products. The biological properties of curcumin, also known as 1,7‐bis (4‐hydroxy‐3‐methoxyphenyl)‐1,6‐heptadiene‐3,5‐dione, or diferuloylmethane, include anti ...
Hudda Ayub +12 more
wiley +1 more source
Role of oxidative stress on diesel-enhanced influenza infection in mice [PDF]
, 2010 Numerous studies have shown that air pollutants, including diesel exhaust (DE), reduce host defenses, resulting in decreased resistance to respiratory infections.
Charly King +6 more
core +4 more sources
European Journal of Immunology, Volume 54, Issue 7, July 2024.IL‐10 and IL‐17 exhibited diverse impacts on regulating MDSCs and airway inflammation. In vitro, IL‐10 deficiency increased polymorphonuclear (PMN)‐MDSC numbers without affecting their suppressive activity in bone marrow, lung, and spleen. In the asthma model, IL‐17 deficiency decreased monocytic (M)‐MDSC numbers and suppressive activity in the lung ...
Charlotte Vetter +7 more
wiley +1 more source
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma [PDF]
, 2011 Background Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses
Joseph M Parker +10 more
core +2 more sources
Physiological Reports, Volume 12, Issue 8, April 2024.Abstract We executed this study to determine if chemerin‐like receptor 1 (CMKLR1), a Gi/o protein‐coupled receptor expressed by leukocytes and non‐leukocytes, contributes to the development of phenotypic features of non‐atopic asthma, including airway hyperresponsiveness (AHR) to acetyl‐β‐methylcholine chloride, lung hyperpermeability, airway ...
Richard A. Johnston +8 more
wiley +1 more source
Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of participants [PDF]
, 2018 Summary.: Objectives: The Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) was designed to investigate the health effects from long-term exposure to air pollution.
Ackermann-Liebrich, Ursula +22 more
core
Biomarkers of Disease and Treatment in Murine and Cynomolgus Models of Chronic Asthma [PDF]
, 2012 Background Biomarkers facilitate early detection of disease and measurement of therapeutic efficacy, both at clinical and experimental levels. Recent advances in analytics and disease models allow comprehensive screening for biomarkers in complex ...
Beaumont, Maribel +12 more
core +3 more sources
Group III secreted phospholipase A2‐driven lysophospholipid pathway protects against allergic asthma
The FASEB Journal, Volume 38, Issue 2, 31 January 2024.This study focuses on the role of group III‐secreted PLA2 (sPLA2‐III) in asthma pathology. sPLA2‐III deficiency exacerbated allergen‐induced asthmatic responses by reducing lysophospholipid levels in the lung. Agonists for lysophosphatidic acid (LPA) receptor 2 reduced TSLP expression in bronchial epithelial cells and reversed airway ...
Asako Hamu‐Tanoue +13 more
wiley +1 more source